- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Microba Life Sciences Ltd (MAP)
The Microba Life Sciences share price today is 0.08, view ASX MAP stock exchange data. Track the latest Microba Life Sciences share price with real-time updates on MAP stock performance including market cap, day range, 52-week range and dividend yield. Access MAP charts, earnings dates and analyst estimates to support your investment decisions.
Sydney
Currency in AUD
0.08
-0.01(-8.54%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.08
0.08
52 wk Range
0.07
0.18
MAP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.080.08
52 wk Range
0.070.18
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
MAP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
0.21
Upside
+156.25%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 0.21
(+156.25% Upside)
Microba Life Sciences Ltd Earnings Call Summary for Q3/2026
- Core testing revenue surged 99% YoY in Q3 FY2026, with testing volumes up 58%, driving strong market traction and growth momentum.
- Company targets regional break-even in Australia and U.K.; FY2026 guidance projects 24,000+ core tests, representing 100% volume growth YoY.
- Major new test launch planned for early FY2027 alongside Clinical Integration Platform to accelerate healthcare provider adoption and revenue.
- Cash reserves limited to approximately 2+ quarters; stock trades at $0.05, down 59% over one year, reflecting investor caution despite growth.
- Management cites 'inflection point' in operations and product advancement, though path to overall profitability remains unrealized amid financial constraints.
Last Updated: 30-04-2026, 07:18 am
Read Full TranscriptEarnings
Latest Release
29-04-2026
EPS / Forecast
-- / --
Revenue / Forecast
3.36M / --
Compare MAP to Peers and Sector
Metrics to compare | MAP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMAPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | 16.1x | −0.5x | |
PEG Ratio | 0.12 | 0.02 | 0.00 | |
Price/Book | 1.6x | 1.3x | 2.6x | |
Price / LTM Sales | 3.3x | 1.1x | 3.2x | |
Upside (Analyst Target) | 156.3% | 40.7% | 50.6% | |
Fair Value Upside | Unlock | 24.4% | 7.1% | Unlock |
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Microba Life Sciences (MAP) Share Price Today?
The Microba Life Sciences share price today is 0.08.
What is the current Microba Life Sciences (MAP) share price and day range?
As of 14-05-2026, the Microba Life Sciences share price is 0.08, with a previous close of 0.08. The share price has ranged from 0.08 to 0.08 today, while the 52-week range spans from 0.07 to 0.18.
What Is the Microba Life Sciences Market Cap?
As of today, Microba Life Sciences market cap is 49.93M.
What Is the Microba Life Sciences (MAP) Share Price Target?
The average 12-month share price target for Microba Life Sciences is 0.21, with a high estimate of 0.29 and a low estimate of 0.12. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +156.25% Upside potential.
What Is Microba Life Sciences's Earnings Per Share (TTM)?
The Microba Life Sciences EPS (TTM) is -0.04.
When Is the Next Microba Life Sciences Earnings Date?
Microba Life Sciences will release its next earnings report on 29-04-2026.
From a Technical Analysis Perspective, Is MAP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Microba Life Sciences Trade On?
Microba Life Sciences is listed and trades on the Sydney Stock Exchange.
What Is the Stock Symbol for Microba Life Sciences?
The stock symbol for Microba Life Sciences is "MAP."
How Many Times Has Microba Life Sciences Stock Split?
Microba Life Sciences has split 0 times.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.